Coronavirus Disease 2019 Vaccination for Cancer Patients: Risk or Benefit?

Abstract Objective The aim of the present study is to list the published clinical trials on coronavirus disease 2019 (COVID-19) vaccines, to describe the mechanism of action of the identified vaccines, and to identify protocols regarding safety, status, and prioritization of cancer patients for vac...

Full description

Bibliographic Details
Main Authors: Bruno Eduardo Pereira Laporte, Estela Gelain Junges Laporte, Paula Fonseca Aarestrup, Matheus Fonseca Aarestrup, Fernando Monteiro Aarestrup
Format: Article
Language:English
Published: Federação Brasileira das Sociedades de Ginecologia e Obstetrícia 2022-08-01
Series:Revista Brasileira de Ginecologia e Obstetrícia
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032022000600602&tlng=en
_version_ 1811321379991060480
author Bruno Eduardo Pereira Laporte
Estela Gelain Junges Laporte
Paula Fonseca Aarestrup
Matheus Fonseca Aarestrup
Fernando Monteiro Aarestrup
author_facet Bruno Eduardo Pereira Laporte
Estela Gelain Junges Laporte
Paula Fonseca Aarestrup
Matheus Fonseca Aarestrup
Fernando Monteiro Aarestrup
author_sort Bruno Eduardo Pereira Laporte
collection DOAJ
description Abstract Objective The aim of the present study is to list the published clinical trials on coronavirus disease 2019 (COVID-19) vaccines, to describe the mechanism of action of the identified vaccines, and to identify protocols regarding safety, status, and prioritization of cancer patients for vaccination. Methods This is a systematic review with a limited literature search conducted by an information specialist; key resources such as PubMed and websites of major cancer organizations were searched. The main search terms were COVID-19, vaccination, cancer, and breast and gynecological cancers. Results Cancer patients infected with the new coronavirus are at high risk of complications and death, but we still know little about the risks and benefits of vaccination for COVID-19 in these patients. In an ideal scenario, all cancer patients should have their immunization status updated before beginning treatment, but this is not always possible. Conclusion Patients with breast or gynecological cancers who are receiving treatment or are in the 5-year posttreatment period should be included in the priority group for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination.
first_indexed 2024-04-13T13:16:45Z
format Article
id doaj.art-de5aba60813946f5996386a17ba0bf12
institution Directory Open Access Journal
issn 0100-7203
language English
last_indexed 2024-04-13T13:16:45Z
publishDate 2022-08-01
publisher Federação Brasileira das Sociedades de Ginecologia e Obstetrícia
record_format Article
series Revista Brasileira de Ginecologia e Obstetrícia
spelling doaj.art-de5aba60813946f5996386a17ba0bf122022-12-22T02:45:28ZengFederação Brasileira das Sociedades de Ginecologia e ObstetríciaRevista Brasileira de Ginecologia e Obstetrícia0100-72032022-08-0144660260810.1055/s-0042-1745788Coronavirus Disease 2019 Vaccination for Cancer Patients: Risk or Benefit?Bruno Eduardo Pereira Laportehttps://orcid.org/0000-0003-3691-2653Estela Gelain Junges Laportehttps://orcid.org/0000-0001-5577-3121Paula Fonseca Aarestruphttps://orcid.org/0000-0001-6623-8941Matheus Fonseca Aarestruphttps://orcid.org/0000-0001-6750-747XFernando Monteiro Aarestruphttps://orcid.org/0000-0001-9226-8271Abstract Objective The aim of the present study is to list the published clinical trials on coronavirus disease 2019 (COVID-19) vaccines, to describe the mechanism of action of the identified vaccines, and to identify protocols regarding safety, status, and prioritization of cancer patients for vaccination. Methods This is a systematic review with a limited literature search conducted by an information specialist; key resources such as PubMed and websites of major cancer organizations were searched. The main search terms were COVID-19, vaccination, cancer, and breast and gynecological cancers. Results Cancer patients infected with the new coronavirus are at high risk of complications and death, but we still know little about the risks and benefits of vaccination for COVID-19 in these patients. In an ideal scenario, all cancer patients should have their immunization status updated before beginning treatment, but this is not always possible. Conclusion Patients with breast or gynecological cancers who are receiving treatment or are in the 5-year posttreatment period should be included in the priority group for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccination.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032022000600602&tlng=encancerCOVID-19vaccinationprotocols
spellingShingle Bruno Eduardo Pereira Laporte
Estela Gelain Junges Laporte
Paula Fonseca Aarestrup
Matheus Fonseca Aarestrup
Fernando Monteiro Aarestrup
Coronavirus Disease 2019 Vaccination for Cancer Patients: Risk or Benefit?
Revista Brasileira de Ginecologia e Obstetrícia
cancer
COVID-19
vaccination
protocols
title Coronavirus Disease 2019 Vaccination for Cancer Patients: Risk or Benefit?
title_full Coronavirus Disease 2019 Vaccination for Cancer Patients: Risk or Benefit?
title_fullStr Coronavirus Disease 2019 Vaccination for Cancer Patients: Risk or Benefit?
title_full_unstemmed Coronavirus Disease 2019 Vaccination for Cancer Patients: Risk or Benefit?
title_short Coronavirus Disease 2019 Vaccination for Cancer Patients: Risk or Benefit?
title_sort coronavirus disease 2019 vaccination for cancer patients risk or benefit
topic cancer
COVID-19
vaccination
protocols
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032022000600602&tlng=en
work_keys_str_mv AT brunoeduardopereiralaporte coronavirusdisease2019vaccinationforcancerpatientsriskorbenefit
AT estelagelainjungeslaporte coronavirusdisease2019vaccinationforcancerpatientsriskorbenefit
AT paulafonsecaaarestrup coronavirusdisease2019vaccinationforcancerpatientsriskorbenefit
AT matheusfonsecaaarestrup coronavirusdisease2019vaccinationforcancerpatientsriskorbenefit
AT fernandomonteiroaarestrup coronavirusdisease2019vaccinationforcancerpatientsriskorbenefit